AI drug discovery Leverage Syntekabio's AI driven drug discovery platform and proprietary supercomputing infrastructure to position as a strategic partner for large pharma seeking accelerated hit generation and novel therapy candidates.

US and SK presence Target cross border collaborations given strong South Korea headquarters and a US hub in New York, offering co development models, translational programs, and regional biotech partnerships.

Asset Programs Capitalise on the recent AI driven Asset Programs launch to offer differentiated antibody and small molecule discovery services, enabling customers to access integrated AI predictions and rapid candidate identification.

Strategic alliances Promote partnerships with academia, industry players, and government labs as a route to collaborative projects, access to datasets, and joint development opportunities that can expand market reach.

Funding and scale Highlight substantial funding and mid market revenue potential to reassure customers and investors while offering scalable engagements, co development deals, and potential for grant aligned programs.